Compare DYAI & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DYAI | KTTA |
|---|---|---|
| Founded | 1979 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 18.1M |
| IPO Year | 2026 | 2021 |
| Metric | DYAI | KTTA |
|---|---|---|
| Price | $0.44 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.7K | 141.8K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,090,345.00 | $486,559.00 |
| Revenue This Year | $113.16 | N/A |
| Revenue Next Year | $94.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $0.34 | $0.28 |
| 52 Week High | $1.60 | $2.06 |
| Indicator | DYAI | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 35.47 |
| Support Level | $0.34 | $0.43 |
| Resistance Level | $0.50 | $0.52 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 56.77 | 9.01 |
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.